IceCure Medical Ltd

NasdaqCM ICCM

IceCure Medical Ltd Return on Equity (ROE) for the year ending December 31, 2023: -120.46%

IceCure Medical Ltd Return on Equity (ROE) is -120.46% for the year ending December 31, 2023. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

IceCure Medical Ltd Return on Equity (ROE) for the year ending December 31, 2020 was -104.23%, a 42.50% change year over year.
IceCure Medical Ltd Return on Equity (ROE) for the year ending December 31, 2019 was -181.26%.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NasdaqCM: ICCM

IceCure Medical Ltd

CEO	Mr. Eyal Shamir
IPO Date	Aug. 26, 2021
Location	Israel
Headquarters	7 Ha’Eshel Street
Employees	71
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Key trends

Past 5 years